In Canada, most patients with advanced G/GEJ adenocarcinoma currently receive HER2, MMR and/or MSI, and PD-L1 testing to support decision-making for targeted first-line therapy. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.